Neisseria meningitidis

Vaccines for Biodefense and Emerging and Neglected Diseases

Volumn , Issue , 2009, Pages 1061-1079

  Rouphael, Nadine G ^a   Zimmer, Shanta M ^a   Stephens, David S ^a,b  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ATLANTA VA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84884435438     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-369408-9.00053-6     Document Type: Chapter

References (230)

1. Meningococcal disease. Secondary attack rate and chemoprophylaxis in the United States, 1974. JAMA 1976; 235(3):261-265.
2. Prevention and control of meningococcal disease: recommendations for use of meningococcal vaccines in pediatric patients. Pediatrics 2005; 116(2):496-505.
3. Safety of meningococcal group C vaccines. Curr. Prob. Pharmacovigil. 2000; 26(14).
4. Centers for Disease Control and Prevention (CDC): Guillain-Barré syndrome among recipients of Menactra meningococcal conjugate vaccine-United States, June 2005-September 2006. MMWR Morb. Mortal. Wkly. Rep. 2006; 55(41):1120-1124.
5. Abramson J.S., Spika J.S. Persistence of Neisseria meningitidis in the upper respiratory tract after intravenous antibiotic therapy for systemic meningococcal disease. J. Infect. Dis. 1985, 151(2):370-371.
6. Alcala B., Arreaza L., Salcedo C., Uria M.J., De La Fuente L., Vazquez J.A. Capsule switching among C:2b:P1.2,5 meningococcal epidemic strains after mass immunization campaign, Spain. Emerg. Infect. Dis. 2002, 8(12):1512-1514.
7. Alonso J.M., Gilmet G., Rouzic E.M., et al. Workshop on vaccine pressure and Neisseria meningitidis, Annecy, France, 9-11 March 2005. Vaccine 2007, 25(21):4125-4129.
8. Alper C.A., Abramson N., Johnston R.B., Jandl J.H., Rosen F.S. Increased susceptibility to infection associated with abnormalities of complement-mediated functions and of the third component of complement (C3). N. Engl. J. Med. 1970, 282(7):350-354.
9. Artenstein M.S., Gold R., Zimmerly J.G., Wyle F.A., Schneider H., Harkins C. Prevention of meningococcal disease by group C polysaccharide vaccine. N. Engl. J. Med. 1970, 282(8):417-420.
10. Artenstein M.S., Rust J.H., Hunter D.H., Lamson T.H., Buescher E.L. Acute respiratory disease and meningococcal infection in army recruits. JAMA 1967, 201(13):1004-1007.
11. Auckland C., Gray S., Borrow R., et al. Clinical and immunologic risk factors for meningococcal C conjugate vaccine failure in the United Kingdom. J. Infect. Dis. 2006, 194(12):1745-1752.
12. Baevsky R.H. Primary meningococcal pericarditis. Clin. Infect. Dis. 1999, 29(1):213-215.
13. Baker M.G., Martin D.R., Kieft C.E., Lennon D. A 10-year serogroup B meningococcal disease epidemic in New Zealand: descriptive epidemiology, 1991-2000. J. Paediatr. Child Health, 2001, 37(5):S13-S19.
14. Balmer P., Borrow R., Miller E. Impact of meningococcal C conjugate vaccine in the UK. J. Med. Microbiol. 2002, 51(9):717-722.
15. Barquet N., Domingo P., Cayla J.A., et al. Prognostic factors in meningococcal disease. Development of a bedside predictive model and scoring system. Barcelona Meningococcal Disease Surveillance Group. JAMA 1997, 278(6):491-496.
16. Bax W.A., Cluysenaer O.J., Bartelink A.K., Aerts P.C., Ezekowitz R.A., van Dijk H. Association of familial deficiency of mannose-binding lectin and meningococcal disease. Lancet 1999, 354(9184):1094-1095.
17. Beernink P.T., Leipus A., Granoff D.M. Rapid genetic grouping of factor h-binding protein (genome-derived neisserial antigen 1870), a promising group B meningococcal vaccine candidate. Clin. Vaccine Immunol. 2006, 13(7):758-763.
18. Benes J., Dzupova O., Kabelkova M., Krizova P., Gabrielova A. Infective endocarditis due to Neisseria meningitidis: two case reports. Clin. Microbiol. Infect. 2003, 9(10):1062-1064.
19. Bergthornorsson G.I., Matthiasson T., Guethnason T., Briem H. Cost-effectiveness analysis on meningococca serogroup C vaccination. Laeknabladid 2004, 90(5):379-383.
20. Bevanger L., Bergh K., Gisnas G., Caugant D.A., Froholm L.O. Identification of nasopharyngeal carriage of an outbreak strain of Neisseria meningitidis by pulsed-field gel electrophoresis versus phenotypic methods. J. Med. Microbiol. 1998, 47(11):993-998.
21. Bilavsky E., Yarden-Bilavsky H., Zevit N., Amir J. Primary meningococcal arthritis in a child: case report and literature review. Scand. J. Infect. Dis. 2006, 38(5):396-399.
22. Bilukha O.O., Rosenstein N. Prevention and control of meningococcal disease. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm. Rep. 2005, 54(RR-7):1-21.
23. Bjune G., Hoiby E.A., Gronnesby J.K., et al. Effect of outer membrane vesicle vaccine against group B meningococcal disease in Norway. Lancet 1991, 338(8775):1093-1096.
24. Blaser M.J., Reingold A.L., Alsever R.N., Hightower A. Primary meningococcal pericarditis: a disease of adults associated with serogroup C Neisseria meningitidis. Rev. Infect. Dis. 1984, 6(5):625-632.
25. Blondeau J.M., Yaschuk Y. In vitro activities of ciprofloxacin, cefotaxime, ceftriaxone, chloramphenicol, and rifampin against fully susceptible and moderately penicillin-resistant Neisseria meningitidis. Antimicrob. Agents Chemother. 1995, 39(11):2577-2579.
26. Boisier P., Nicolas P., Djibo S., et al. Meningococcal meningitis: unprecedented incidence of serogroup X-related cases in 2006 in Niger. Clin. Infect. Dis. 2007, 44(5):657-663.
27. Booy R., Jelfs J., El Bashir H., Nissen M.D. Impact of meningococcal C conjugate vaccine use in Australia. Med. J. Aust. 2007, 186(3):108-109.
28. Borrow R., Balmer P., Miller E. Meningococcal surrogates of protection-serum bactericidal antibody activity. Vaccine 2005, 23(17-18):2222-2227.
29. Borrow R., Longworth E., Gray S.J., Kaczmarski E.B. Prevalence of de-O-acetylated serogroup C meningococci before the introduction of meningococcal serogroup C conjugate vaccines in the United Kingdom. FEMS Immunol. Med. Microbiol. 2000, 28(3):189-191.
30. Boslego J., Garcia J., Cruz C., et al. Efficacy, safety, and immunogenicity of a meningococcal group B (15:P1.3) outer membrane protein vaccine in Iquique, Chile. Chilean National Committee for Meningococcal Disease. Vaccine 1995, 13(9):821-829.
31. Bowe F., Lavelle E.C., McNeela E.A., et al. Mucosal vaccination against serogroup B meningococci: induction of bactericidal antibodies and cellular immunity following intranasal immunization with NadA of Neisseria meningitidis and mutants of Escherichia coli heat-labile enterotoxin. Infect. Immun. 2004, 72(7):4052-4060.
32. Brandtzaeg P., Bryn K., Kierulf P., et al. Meningococcal endotoxin in lethal septic shock plasma studied by gas chromatography, mass-spectrometry, ultracentrifugation, and electron microscopy. J. Clin. Invest. 1992, 89(3):816-823.
33. Branham S. Serological relationships among meningococci. Bacteriol. Rev. 1953, 17:175-188.
34. Brooks R., Woods C.W., Benjamin D.K., Rosenstein N.E. Increased case-fatality rate associated with outbreaks of Neisseria meningitidis infection, compared with sporadic meningococcal disease, in the United States, 1994-2002. Clin. Infect. Dis. 2006, 43(1):49-54.
35. Bruge J., Bouveret-Le Cam N., Danve B., Rougon G., Schulz D. Clinical evaluation of a group B meningococcal N-propionylated polysaccharide conjugate vaccine in adult, male volunteers. Vaccine 2004, 22(9-10):1087-1096.
36. Brundage J.F., Ryan M.A., Feighner B.H., Erdtmann F.J. Meningococcal disease among United States military service members in relation to routine uses of vaccines with different serogroup-specific components, 1964-1998. Clin. Infect. Dis. 2002, 35(11):1376-1381.
37. Bryant P.A., Li H.Y., Zaia A., et al. Prospective study of a real-time PCR that is highly sensitive, specific, and clinically useful for diagnosis of meningococcal disease in children. J. Clin. Microbiol. 2004, 42(7):2919-2925.
38. Buttery J.P., Riddell A., McVernon J., et al. Immunogenicity and safety of a combination pneumococcal-meningococcal vaccine in infants: a randomized controlled trial. JAMA 2005, 293(14):1751-1758.
39. Campagne G., Garba A., Fabre P., et al. Safety and immunogenicity of three doses of a Neisseria meningitidis A+C diphtheria conjugate vaccine in infants from Niger. Pediatr. Infect. Dis. J. 2000, 19(2):144-150.
40. Cartwright K., Noah N., Peltola H. Meningococcal disease in Europe: epidemiology, mortality, and prevention with conjugate vaccines. Report of a European advisory board meeting Vienna, Austria, 6-8 October, 2000. Vaccine 2001, 19(31):4347-4356.
41. Cartwright K., Reilly S., White D., Stuart J. Early treatment with parenteral penicillin in meningococcal disease. BMJ 1992, 305(6846):143-147.
42. Casella E.B., Cypel S., Osmo A.A., et al. Sequelae from meningococcal meningitis in children: a critical analysis of dexamethasone therapy. Arq. Neuropsiquiatr. 2004, 62(2B):421-428.
43. Castagliuolo P.P., Nisini R., Quinti I., Fattorossi A., D'Amelio R. Immunoglobulin deficiencies and meningococcal disease. Ann. Allergy, 1986, 57(1):68-70.
44. Caugant D.A. Population genetics and molecular epidemiology of Neisseria meningitidis. APMIS 1998, 106(5):505-525.
45. Caugant D.A., Froholm L.O., Bovre K., et al. Intercontinental spread of a genetically distinctive complex of clones of Neisseria meningitidis causing epidemic disease. Proc. Natl. Acad. Sci. U.S.A. 1986, 83(13):4927-4931.
46. Caugant D.A., Hoiby E.A., Magnus P., et al. Asymptomatic carriage of Neisseria meningitidis in a randomly sampled population. J. Clin. Microbiol. 1994, 32(2):323-330.
47. Chow A.W., Culver B., Yoshikawa T.T., Guze L.B. Primary meningococcal pericarditis presenting with tamponade. Chest 1975, 67(5):611-612.
48. Comanducci M., Bambini S., Brunelli B., et al. NadA, a novel vaccine candidate of Neisseria meningitidis. J. Exp. Med. 2002, 195(11):1445-1454.
49. Costantino P., Viti S., Podda A., Velmonte M.A., Nencioni L., Rappuoli R. Development and phase 1 clinical testing of a conjugate vaccine against meningococcus A and C. Vaccine 1992, 10(10):691-698.
50. Danielson L., Mann E. A history of a singular and very noted disease, which lately made its appearance in Medfield. Med. Agric. Reg. 1806, 1:65-69.
51. D'Antuono A., Andalo F., Varotti C. Acute urethritis due to Neisseria meningitidis. Sex. Transm. Infect. 1999, 75(5):362.
52. Decosas J., Koama J.B. Chronicle of an outbreak foretold: meningococcal meningitis W135 in Burkina Faso. Lancet Infect. Dis. 2002, 2(12):763-765.
53. de Jonge M.I., Hamstra H.J., Jiskoot W., et al. Intranasal immunisation of mice with liposomes containing recombinant meningococcal OpaB and OpaJ proteins. Vaccine 2004, 22(29-30):4021-4028.
54. de Jonge M.I., Vidarsson G., van Dijken H.H., et al. Functional activity of antibodies against the recombinant OpaJ protein from Neisseria meningitidis. Infect. Immun. 2003, 71(5):2331-2340.
55. de Kleijn E.D., de Groot R., Hack C.E., et al. Activation of protein C following infusion of protein C concentrate in children with severe meningococcal sepsis and purpura fulminans: a randomized, double-blinded, placebo-controlled, dose-finding study. Crit. Care Med. 2003, 31(6):1839-1847.
56. de Kleijn E.D., de Groot R., Labadie J., et al. Immunogenicity and safety of a hexavalent meningococcal outer-membrane-vesicle vaccine in children of 2-3 and 7-8 years of age. Vaccine 2000, 18(15):1456-1466.
57. de Kleijn E.D., de Groot R., Lafeber A.B., et al. Immunogenicity and safety of monovalent p1.7(h),4 meningococcal outer membrane vesicle vaccine in toddlers: comparison of two vaccination schedules and two vaccine formulations. Vaccine 2000, 19(9-10):1141-1148.
58. Dell E., Bedford D., McMahon B., Nicholson A. Meningococcal disease-management of serogroup C clusters in a hyperendemic area. Ir. Med. J. 2001, 94(6):166. Comment: 168-169.
59. de Moraes J.C., Perkins B.A., Camargo M.C., et al. Protective efficacy of a serogroup B meningococcal vaccine in Sao Paulo, Brazil. Lancet 1992, 340(8827):1074-1078.
60. Densen P. Complement deficiencies and meningococcal disease. Clin. Exp. Immunol. 1991, 86(Suppl. 1):57-62.
61. De Queiros L., Castro L., Ferreira M.C., Goncalves G. [Acceptance of the new conjugate vaccines. Meningococcal and pneumococcal vaccines, in the cohort born in 1999, in the North Region of Portugal]. Acta Med. Port. 2004, 17(1):49-53.
62. De Schrijver K., Maes I. An outbreak of serogroup C meningococcal disease in the province of Antwerp (Belgium) in 2001-2002. Eur. J. Epidemiol. 2003, 18(11):1073-1077.
63. Devoy A.F., Dyet K.H., Martin D.R. Stability of PorA during a meningococcal disease epidemic. J. Clin. Microbiol. 2005, 43(2):832-837.
64. De Wals P., Deceuninck G., Boulianne N., De Serres G. Effectiveness of a mass immunization campaign using serogroup C meningococcal conjugate vaccine. JAMA 2004, 292(20):2491-2494.
65. De Wals P., Hertoghe L., Borlee-Grimee I., et al. Meningococcal disease in Belgium. Secondary attack rate among household, day-care nursery and pre-elementary school contacts. J. Infect. 1981, 3(Suppl. 1):53-61.
66. Diggle M.A., Clarke S.C. Increased genetic diversity of Neisseria meningitidis isolates after the introduction of meningococcal serogroup C polysaccharide conjugate vaccines. J. Clin. Microbiol. 2005, 43(9):4649-4653.
67. Dyet K.H., Martin D.R. Sequence variation in the porB gene from B:P1.4 meningococci causing New Zealand's epidemic. J. Clin. Microbiol. 2005, 43(2):838-842.
68. Edwards M.S., Baker C.J. Complications and sequelae of meningococcal infections in children. J. Pediatr. 1981, 99(4):540-545.
69. El Bashir H., Klaber R., El Baki A., Booy R. W135 meningococcal pericarditis: report of two cases and review of the literature. Pediatr. Infect. Dis. J. 2004, 23(10):969-970.
70. Ellison R.T., Kohler P.F., Curd J.G., Judson F.N., Reller L.B. Prevalence of congenital or acquired complement deficiency in patients with sporadic meningococcal disease. N. Engl. J. Med. 1983, 308(16):913-916.
71. Emonts M., Hazelzet J.A., de Groot R., Hermans P.W. Host genetic determinants of Neisseria meningitidis infections. Lancet Infect. Dis. 2003, 3(9):565-577.
72. Erickson L.J., De Wals P., McMahon J., Heim S. Complications of meningococcal disease in college students. Clin. Infect. Dis. 2001, 33(5):737-739.
73. Ferry N., Steele A. Active immunization with meningococcus toxin. JAMA 1935, 104:983-984.
74. Fijen C.A., Kuijper E.J., Hannema A.J., Sjoholm A.G., van Putten J.P. Complement deficiencies in patients over ten years old with meningococcal disease due to uncommon serogroups. Lancet 1989, 2(8663):585-588.
75. Fijen C.A., Kuijper E.J., te Bulte M.T., Daha M.R., Dankert J. Assessment of complement deficiency in patients with meningococcal disease in The Netherlands. Clin. Infect. Dis. 1999, 28(1):98-105.
76. Finne J., Leinonen M., Makela P.H. Antigenic similarities between brain components and bacteria causing meningitis. Implications for vaccine development and pathogenesis. Lancet 1983, 2(8346):355-357.
77. Fischer M., Hedberg K., Cardosi P., et al. Tobacco smoke as a risk factor for meningococcal disease. Pediatr. Infect. Dis. J. 1997, 16(10):979-983.
78. Flexner S. The results if the serum treatment in thirteen hundred cases of epidemic meningitis. J. Exp. Med. 1913, 17:553.
79. Frasch C.E., Zollinger W.D., Poolman J.T. Serotype antigens of Neisseria meningitidis and a proposed scheme for designation of serotypes. Rev. Infect. Dis. 1985, 7(4):504-510.
80. Fraser A., Gafter-Gvili A., Paul M., Leibovici L. Antibiotics for preventing meningococcal infections. Cochrane Database Syst. Rev. 2006, 4. CD004785.
81. Gagneux S.P., Hodgson A., Smith T.A., et al. Prospective study of a serogroup X Neisseria meningitidis outbreak in northern Ghana. J. Infect. Dis. 2002, 185(5):618-626.
82. Garcia N.S., Castelo J.S., Ramos V., Rezende G.S., Pereira F.E. Frequency of myocarditis in cases of fatal meningococcal infection in children: observations on 31 cases studied at autopsy. Rev. Soc. Bras. Med. Trop. 1999, 32(5):517-522.
83. Gates F. A report on antimeningitis vaccination and observations on agglutinins in the blood of chronic meningococcus carriers. J. Exp. Med. 1918, 28:449-474.
84. Gilmore A., Stuart J., Andrews N. Risk of secondary meningococcal disease in health-care workers. Lancet 2000, 356(9242):1654-1655.
85. Girgis N., Sultan Y., Frenck R.W., El-Gendy A., Farid Z., Mateczun A. Azithromycin compared with rifampin for eradication of nasopharyngeal colonization by Neisseria meningitidis. Pediatr. Infect. Dis. J. 1998, 17(9):816-819.
86. Giuliani M.M., Adu-Bobie J., Comanducci M., et al. A universal vaccine for serogroup B meningococcus. Proc. Natl. Acad. Sci. U.S.A. 2006, 103(29):10834-10839.
87. Glover J. The cerebrospinal fever epidemic of 1917 at "X" depot. J. R. Army Med. Corps 1918, 30:23.
88. Gold R., Lepow M.L., Goldschneider I., Draper T.F., Gotshlich E.C. Kinetics of antibody production to group A and group C meningococcal polysaccharide vaccines administered during the first six years of life: prospects for routine immunization of infants and children. J. Infect. Dis. 1979, 140(5):690-697.
89. Goldacre M.J., Roberts S.E., Yeates D. Case fatality rates for meningococcal disease in an English population, 1963-98: database study. BMJ. 2003, 327(7415):596-597.
90. Goldschneider I., Gotschlich E.C., Artenstein M.S. Human immunity to the meningococcus. I. The role of humoral antibodies. J. Exp. Med. 1969, 129(6):1307-1326.
91. Goldschneider I., Gotschlich E.C., Artenstein M.S. Human immunity to the meningococcus. II. Development of natural immunity. J. Exp. Med. 1969, 129(6):1327-1348.
92. Gomez J.A., Criado M.T., Ferreiros C.M. Bactericidal activity of antibodies elicited against the Neisseria meningitidis 37-kDa ferric binding protein (FbpA) with different adjuvants. FEMS Immunol. Med. Microbiol. 1998, 20(1):79-86.
93. Gorringe A.R. Can Neisseria lactamica antigens provide an effective vaccine to prevent meningococcal disease?. Expert Rev. Vaccines 2005, 4(3):373-379.
94. Gotschlich E.C., Goldschneider I., Artenstein M.S. Human immunity to the meningococcus. IV. Immunogenicity of group A and group C meningococcal polysaccharides in human volunteers. J. Exp. Med. 1969, 129(6):1367-1384.
95. Gotschlich E.C., Liu T.Y., Artenstein M.S. Human immunity to the meningococcus. 3. Preparation and immunochemical properties of the group A, group B, and group C meningococcal polysaccharides. J. Exp. Med. 1969, 129(6):1349-1365.
96. Granoff D.M., Bartoloni A., Ricci S., et al. Bactericidal monoclonal antibodies that define unique meningococcal B polysaccharide epitopes that do not cross-react with human polysialic acid. J. Immunol. 1998, 160(10):5028-5036.
97. Granoff D.M., Kelsey S.K., Bijlmer H.A., et al. Antibody responses to the capsular polysaccharide of Neisseria meningitidis serogroup B in patients with meningococcal disease. Clin. Diagn. Lab. Immunol. 1995, 2(5):574-582.
98. Greenfield S., Sheehe P.R., Feldman H.A. Meningococcal carriage in a population of "normal" families. J. Infect. Dis. 1971, 123(1):67-73.
99. Greenwood B. Manson Lecture. Meningococcal meningitis in Africa. Trans. R. Soc. Trop. Med. Hyg. 1999, 93(4):341-353.
100. Greenwood B.M., Bradley A.K., Wall R.A. Meningococcal disease and season in sub-Saharan Africa. Lancet 1985, 2(8459):829-830.
101. Greenwood B.M., Greenwood A.M., Bradley A.K., et al. Factors influencing susceptibility to meningococcal disease during an epidemic in The Gambia, West Africa. J. Infect. 1987, 14(2):167-184.
102. Gupta S., Tuladhar A.B. Does early administration of dexamethasone improve neurological outcome in children with meningococcal meningitis?. Arch. Dis. Child. 2004, 89(1):82-83.
103. Hadi H.A., Wooldridge K.G., Robinson K., Ala'Aldeen D.A. Identification and characterization of App: an immunogenic autotransporter protein of Neisseria meningitidis. Mol. Microbiol. 2001, 41(3):611-623.
104. Hagman M., Forslin L., Moi H., Danielsson D. Neisseria meningitidis in specimens from urogenital sites. Is increased awareness necessary?. Sex. Transm. Dis. 1991, 18(4):228-232.
105. Hahne S.J., Gray S.J., Jean F., et al. W135 meningococcal disease in England and Wales associated with Hajj 2000 and 2001. Lancet 2002, 359(9306):582-583.
106. Halperin S.A., Langley J.M., Smith B., et al. Phase 1 first-in-human studies of the reactogenicity and immunogenicity of a recombinant meningococcal NspA vaccine in healthy adults. Vaccine 2007, 25(3):450-457.
107. Hardman J.M., Earle K.M. Myocarditis in 200 fatal meningococcal infections. Arch. Pathol. 1969, 87(3):318-325.
108. Harrison L.H., Dwyer D.M., Maples C.T., Billmann L. Risk of meningococcal infection in college students. JAMA 1999, 281(20):1906-1910.
109. Hart C.A., Cuevas L.E. Meningococcal disease in Africa. Ann. Trop. Med. Parasitol. 1997, 91(7):777-785.
110. Hassan-King M.K., Wall R.A., Greenwood B.M. Meningococcal carriage, meningococcal disease and vaccination. J. Infect. 1988, 16(1):55-59.
111. Heath P.T. Haemophilus influenzae type b conjugate vaccines: a review of efficacy data. Pediatr. Infect. Dis. J. 1998, 17(Suppl. 9):S117-S122.
112. Hibberd M.L., Sumiya M., Summerfield J.A., Booy R., Levin M. Association of variants of the gene for mannose-binding lectin with susceptibility to meningococcal disease. Meningococcal Research Group. Lancet 1999, 353(9158):1049-1053.
113. Jackson L.A., Schuchat A., Reeves M.W., Wenger J.D. Serogroup C meningococcal outbreaks in the United States. An emerging threat. JAMA 1995, 273(5):383-389.
114. Joao I., Marques P., Namora J., et al. Neisseria meningitidis native valve endocarditis. A case report. Rev. Port. Cardiol. 2001, 20(9):877-880.
115. Johnson A.S., Gorringe A.R., Mackinnon F.G., Fox A.J., Borrow R., Robinson A. Analysis of the human Ig isotype response to lactoferrin binding protein A from Neisseria meningitidis. FEMS Immunol. Med. Microbiol. 1999, 25(4):349-354.
116. Kahler C.M., Stephens D.S. Genetic basis for biosynthesis, structure, and function of meningococcal lipooligosaccharide (endotoxin). Crit. Rev. Microbiol. 1998, 24(4):281-334.
117. Kasper D.L., Fauci A.S., Longo D.L., Braunwald E., Hauser S.L., Jameson J.L. Harrison's Principles of Internal Medicine 2005, McGraw-Hill Companies. 16th ed.
118. Kaplan S.L., Schutze G.E., Leake J.A., et al. Multicenter surveillance of invasive meningococcal infections in children. Pediatrics 2006, 118(4):e979-e984.
119. Karolus J.J., Gandelman A.L., Nolan B.A. Urethritis caused by Neisseria meningitidis. J. Clin. Microbiol. 1980, 12(2):284-285.
120. Kayhty H., Jousimies-Somer H., Peltola H., Maketa P.H. Antibody response to capsular polysaccharides of groups A and C Neisseria meningitidis and Haemophilus influenzae type b during bacteremic disease. J. Infect. Dis. 1981, 143(1):32-41.
121. Kelly D.F., Snape M.D., Clutterbuck E.A., et al. CRM197-conjugated serogroup C meningococcal capsular polysaccharide, but not the native polysaccharide, induces persistent antigen-specific memory B cells. Blood 2006, 108(8):2642-2647.
122. Khuns D., Kisner P., Williams M., Moorman P. The control of meningococcic meningitis epidemics by active immunization with meningococcus soluble toxin: further studies. JAMA 1938, 110:484-487.
123. Khuns D., Nelson C., Feldman H.A., et al. The prophylactic value of sulfadiazine in the control of meningococcic meningitis. JAMA 1943, 123:335-339.
124. Kiefer F. Zur differential Diagnose des Erregers der epidemischen Cerebrospinalmeningitis und der Gonorrhoea. Berl. Klin. Wochenschr. 1896, 33:628.
125. Koumare B., Ouedraogo-Traore R., Sanou I., et al. The first large epidemic of meningococcal disease caused by serogroup W135, Burkina Faso, 2002. Vaccine 2007, 25(Suppl 1):A37-A41.
126. Laforce F.M., Konde K., Viviani S., Preziosi M.P. The Meningitis Vaccine Project. Vaccine 2007, 25(Suppl 1):A97-A100.
127. Leach A., Twumasi P.A., Kumah S., et al. Induction of immunologic memory in Gambian children by vaccination in infancy with a group A plus group C meningococcal polysaccharide-protein conjugate vaccine. J. Infect. Dis. 1997, 175(1):200-204.
128. Lehmann A.K., Gorringe A.R., Reddin K.M., West K., Smith I., Halstensen A. Human opsonins induced during meningococcal disease recognize transferrin binding protein complexes. Infect. Immun. 1999, 67(12):6526-6532.
129. Lepeyssonnie L. La meningite cerebrospinale en Afrique. Bull. World Health Organ. 1963, 28(Suppl.):53-114.
130. Lepow M.L., Beeler J., Randolph M., Samuelson J.S., Hankins W.A. Reactogenicity and immunogenicity of a quadrivalent combined meningococcal polysaccharide vaccine in children. J. Infect. Dis. 1986, 154(6):1033-1036.
131. Lewis R., Nathan N., Diarra L., Belanger F., Paquet C. Timely detection of meningococcal meningitis epidemics in Africa. Lancet 2001, 358(9278):287-293.
132. Li Y., Zhang Q., Winterbotham M., Mowe E., Gorringe A., Tang C.M. Immunization with live Neisseria lactamica protects mice against meningococcal challenge and can elicit serum bactericidal antibodies. Infect. Immun. 2006, 74(11):6348-6355.
133. Lingappa J.R., Al-Rabeah A.M., Hajjeh R., et al. Serogroup W-135 meningococcal disease during the Hajj, 2000. Emerg. Infect. Dis. 2003, (6):665-671.
134. MacLennan J., Obaro S., Deeks J., et al. Immune response to revaccination with meningococcal A and C polysaccharides in Gambian children following repeated immunisation during early childhood. Vaccine 1999, 17(23-24):3086-3093.
135. Maiden M.C., Bygraves J.A., Feil E., et al. Multilocus sequence typing: a portable approach to the identification of clones within populations of pathogenic microorganisms. Proc. Natl. Acad. Sci. U.S.A. 1998, 95(6):3140-3145.
136. Maiden M.C., Spratt B.G. Meningococcal conjugate vaccines: new opportunities and new challenges. Lancet 1999, 354(9179):615-616.
137. Maiden M.C., Stuart J.M. Carriage of serogroup C meningococci 1 year after meningococcal C conjugate polysaccharide vaccination. Lancet 2002, 359(9320):1829-1831.
138. Mandrell R.E., Azmi F.H., Granoff D.M. Complement-mediated bactericidal activity of human antibodies to poly alpha 2→8 N-acetylneuraminic acid, the capsular polysaccharide of Neisseria meningitidis serogroup B. J. Infect. Dis. 1995, 172(5):1279-1289.
139. Martin D., Cadieux N., Hamel J., Brodeur B.R. Highly conserved Neisseria meningitidis surface protein confers protection against experimental infection. J. Exp. Med. 1997, 185(7):1173-1183.
140. Masterton R.G., Youngs E.R., Wardle J.C., Croft K.F., Jones D.M. Control of an outbreak of group C meningococcal meningitis with a polysaccharide vaccine. J. Infect. 1988, 17(2):177-182.
141. Mattila P.S., Carlson P. Pharyngolaryngitis caused by Neisseria meningitidis. Scand. J. Infect. Dis. 1998, 30(2):198-200.
142. McCrumb F., Hall H., Merideth A. Chloramphenicol in the treatment of meningococcal meningitis. Am. J. Med. 1951, 10:696.
143. Miller E., Salisbury D., Ramsay M. Planning, registration, and implementation of an immunisation campaign against meningococcal serogroup C disease in the UK: a success story. Vaccine 2001, 20(Suppl. 1):S58-S67.
144. Miller M.A., Millikin P., Griffin P.S., Sexton R.A., Yousuf M. Neisseria meningitidis urethritis. A case report. JAMA 1979, 242(15):1656-1657.
145. Moe G.R., Dave A., Granoff D.M. Molecular analysis of anti-N-propionyl Neisseria meningitidis group B polysaccharide monoclonal antibodies. Mol. Immunol. 2006, 43(9):1424-1431.
146. Moe G.R., Zuno-Mitchell P., Lee S.S., Lucas A.H., Granoff D.M. Functional activity of anti-Neisserial surface protein A monoclonal antibodies against strains of Neisseria meningitidis serogroup B. Infect. Immun. 2001, 69(6):3762-3771.
147. Moore P.S., Hierholzer J., DeWitt W., et al. Respiratory viruses and mycoplasma as cofactors for epidemic group A meningococcal meningitis. JAMA 1990, 264(10):1271-1275.
148. Moraga F.A., Domingo P., Barquet N., Gasser I., Gallart A. Invasive meningococcal conjunctivitis. JAMA 1990, 264(3):333-334.
149. Morgan D.R., Spence M., Crowe M., O'Keeffe D.B. Primary (isolated) meningococcal pericarditis. Clin. Cardiol. 2002, 25(6):305-307.
150. Mothershed E.A., Sacchi C.T., Whitney A.M., et al. Use of real-time PCR to resolve slide agglutination discrepancies in serogroup identification of Neisseria meningitidis. J. Clin. Microbiol. 2004, 42(1):320-328.
151. Nadel S., Goldstein B., Williams M.D., et al. Drotrecogin alfa (activated) in children with severe sepsis: a multicentre phase III randomised controlled trial. Lancet 2007, 369(9564):836-843.
152. Newcombe J., Cartwright K., Palmer W.H., McFadden J. PCR of peripheral blood for diagnosis of meningococcal disease. J. Clin. Microbiol. 1996, 34(7):1637-1640.
153. Newton D.A., Wilson W.G. Primary meningococcal conjunctivitis. Pediatrics 1977, 60(1):104-106.
154. Ni H., Knight A.I., Cartwright K., Palmer W.H., McFadden J. Polymerase chain reaction for diagnosis of meningococcal meningitis. Lancet 1992, 340(8833):1432-1434.
155. Nicholson A., Lepow I.H. Host defense against Neisseria meningitidis requires a complement-dependent bactericidal activity. Science 1979, 205(4403):298-299.
156. Nielsen H.E., Koch C., Magnussen P., Lind I. Complement deficiencies in selected groups of patients with meningococcal disease. Scand. J. Infect. Dis. 1989, 21(4):389-396.
157. Nielsen L.T. Chronic meningococcemia. Arch. Dermatol. 1970, 102(1):97-101.
158. Niklasson P.M., Lundbergh P., Strandell T. Prognostic factors in meningococcal disease. Scand. J. Infect. Dis. 1971, 3(1):17-25.
159. Noronha C.P., Struchiner C.J., Halloran M.E. Assessment of the direct effectiveness of BC meningococcal vaccine in Rio de Janeiro, Brazil: a case-control study. Int. J. Epidemiol. 1995, 24(5):1050-1057.
160. Odegaard K., Gundersen T. Isolation of Neisseria meningitidis in urogenital/rectal infections. Acta Derm. Venereol. 1977, 57(2):173-176.
161. O'Hallahan J., Lennon D., Oster P. The strategy to control New Zealand's epidemic of group B meningococcal disease. Pediatr. Infect. Dis. J. 2004, 23(Suppl. 12):S293-S298.
162. Olsen S.F., Djurhuus B., Rasmussen K., et al. Pharyngeal carriage of Neisseria meningitidis and Neisseria lactamica in households with infants within areas with high and low incidences of meningococcal disease. Epidemiol. Infect. 1991, 106(3):445-457.
163. Ouedraogo-Traore R., Hoiby E.A., Sanou I., et al. Molecular characteristics of Neisseria meningitidis strains isolated in Burkina Faso in 2001. Scand. J. Infect. Dis. 2002, 34(11):804-807.
164. Pether J.V., Scott R.J., Hancock P. Do meningococci cause sore throats?. Lancet 1994, 344(8937):1636.
165. Pichichero M., Casey J., Blatter M., et al. Comparative trial of the safety and immunogenicity of quadrivalent (A, C, Y, W-135) meningococcal polysaccharide-diphtheria conjugate vaccine versus quadrivalent polysaccharide vaccine in two- to ten-year-old children. Pediatr. Infect. Dis. J. 2005, 24(1):57-62.
166. Pillai S., Howell A., Alexander K., et al. Outer membrane protein (OMP) based vaccine for Neisseria meningitidis serogroup B. Vaccine 2005, 23(17-18):2206-2209.
167. Pizza M., Scarlato V., Masignani V., et al. Identification of vaccine candidates against serogroup B meningococcus by whole-genome sequencing. Science 2000, 287(5459):1816-1820.
168. Plested J.S., Harris S.L., Wright J.C., et al. Highly conserved Neisseria meningitidis inner-core lipopolysaccharide epitope confers protection against experimental meningococcal bacteremia. J. Infect. Dis. 2003, 187(8):1223-1234.
169. Ramsay M.E., Andrews N.J., Trotter C.L., Kaczmarski E.B., Miller E. Herd immunity from meningococcal serogroup C conjugate vaccination in England: database analysis. BMJ 2003, 326(7385):365-366.
170. Richmond P., Borrow R., Miller E., et al. Meningococcal serogroup C conjugate vaccine is immunogenic in infancy and primes for memory. J. Infect. Dis. 1999, 179(6):1569-1572.
171. Rosenqvist E., Musacchio A., Aase A., et al. Functional activities and epitope specificity of human and murine antibodies against the class 4 outer membrane protein (Rmp) of Neisseria meningitidis. Infect. Immun. 1999, 67(3):1267-1276.
172. Rosenstein N.E., Perkins B.A., Stephens D.S., Popovic T., Hughes J.M. Meningococcal disease. N. Engl. J. Med. 2001, 344(18):1378-1388.
173. Rosenstein N.E., Perkins B.A., Stephens D.S., et al. The changing epidemiology of meningococcal disease in the United States, 1992-1996. J. Infect. Dis. 1999, 180(6):1894-1901.
174. Ruggeberg J.U., Pollard A.J. Meningococcal vaccines. Paediatr. Drugs 2004, 6(4):251-266.
175. Salleras L., Dominguez A., Cardenosa N. Impact of mass vaccination with polysaccharide conjugate vaccine against serogroup C meningococcal disease in Spain. Vaccine 2003, 21(7-8):725-728.
176. Schaad U.B. Arthritis in disease due to Neisseria meningitidis. Rev. Infect. Dis. 1980, 2(6):880-888.
177. Schoenback E., Phair J. The sensitivity of meningococci to sulfadiazine. Am. J. Hyg. 1948, 47:177-186.
178. Schryvers A.B., Stojiljkovic I. Iron acquisition systems in the pathogenic Neisseria. Mol. Microbiol. 1999, 32(6):1117-1123.
179. Schwentker F., Gelman S., Long P. The treatment of meningococcic meningitis with sulfonamide. Preliminary report. JAMA 1937, 108:1407.
180. Sejvar J.J., Johnson D., Popovic T., et al. Assessing the risk of laboratory-acquired meningococcal disease. J. Clin. Microbiol. 2005, 43(9):4811-4814.
181. Sexton K., Lennon D., Oster P., et al. Proceedings of the meningococcal vaccine strategy World Health Organization satellite meeting, 10 March 2004, Auckland, New Zealand. N.Z. Med. J. 2004, 117(1200). 1 p. preceding U1027.
182. Sharip A., Sorvillo F., Redelings M.D., Mascola L., Wise M., Nguyen D.M. Population-based analysis of meningococcal disease mortality in the United States: 1990-2002. Pediatr. Infect. Dis. J. 2006, 25(3):191-194.
183. Sierra G.V., Campa H.C., Varcacel N.M., et al. Vaccine against group B Neisseria meningitidis: protection trial and mass vaccination results in Cuba. NIPH Ann. 1991, 14(2):195-207. discussion 208-210.
184. Snape M.D., Pollard A.J. Meningococcal polysaccharide-protein conjugate vaccines. Lancet Infect. Dis. 2005, 5(1):21-30.
185. Sophian A., Black J. Prophylactic vaccination against epidemic meningitis. JAMA 1912, 59:527-532.
186. Southern J., Crowley-Luke A., Borrow R., Andrews N., Miller E. Immunogenicity of one, two or three doses of a meningococcal C conjugate vaccine conjugated to tetanus toxoid, given as a three-dose primary vaccination course in UK infants at 2, 3 and 4 months of age with acellular pertussis-containing DTP/Hib vaccine. Vaccine 2006, 24(2):215-219.
187. Stein D.M., Robbins J., Miller M.A., Lin F.Y., Schneerson R. Are antibodies to the capsular polysaccharide of Neisseria meningitidis group B and Escherichia coli K1 associated with immunopathology?. Vaccine 2006, 24(3):221-228.
188. Stephens D.S. Uncloaking the meningococcus: dynamics of carriage and disease. Lancet 1999, 353(9157):941-942.
189. Stephens D.S., Greenwood B., Brandtzaeg P. Epidemic meningitis, meningococcaemia, and Neisseria meningitidis. Lancet 2007, 369(9580):2196-2210.
190. Stephens D.S., Hajjeh R.A., Baughman W.S., Harvey R.C., Wenger J.D., Farley M.M. Sporadic meningococcal disease in adults: results of a 5-year population-based study. Ann. Intern. Med. 1995, 123(12):937-940.
191. Stephens D.S., Whitney A.M., Rothbard J., Schoolnik G.K. Pili of Neisseria meningitidis. Analysis of structure and investigation of structural and antigenic relationships to gonococcal pili. J. Exp. Med. 1985, 161(6):1539-1553.
192. Stephens D.S., Zimmer S.M. Pathogenesis, therapy, and prevention of meningococcal sepsis. Curr. Infect. Dis. Rep. 2002, 4(5):377-386.
193. Sullivan T.D., LaScolea L.J. Neisseria meningitidis bacteremia in children: quantitation of bacteremia and spontaneous clinical recovery without antibiotic therapy. Pediatrics 1987, 80(1):63-67.
194. Swartley J.S., Marfin A.A., Edupuganti S., et al. Capsule switching of Neisseria meningitidis. Proc. Natl. Acad. Sci. U.S.A. 1997, 94(1):271-276.
195. Tappero J.W., Lagos R., Ballesteros A.M., et al. Immunogenicity of 2 serogroup B outer-membrane protein meningococcal vaccines: a randomized controlled trial in Chile. JAMA 1999, 281(16):1520-1527.
196. Tejedor J.C., Moro M., Ruiz-Contreras J., et al. Immunogenicity and reactogenicity of primary immunization with a novel combined Haemophilus influenzae type b and Neisseria meningitidis serogroup C-tetanus toxoid conjugate vaccine coadministered with a diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated poliovirus vaccine at 2, 4 and 6 months. Pediatr. Infect. Dis. J. 2007, 26(1):1-7.
197. Thompson E.A., Feavers I.M., Maiden M.C. Antigenic diversity of meningococcal enterobactin receptor FetA, a vaccine component. Microbiology 2003, 149(Pt. 7):1849-1858.
198. Thompson M.J., Ninis N., Perera R., et al. Clinical recognition of meningococcal disease in children and adolescents. Lancet 2006, 367(9508):397-403.
199. Thornton V., Lennon D., Rasanathan K., et al. Safety and immunogenicity of New Zealand strain meningococcal serogroup B OMV vaccine in healthy adults: beginning of epidemic control. Vaccine 2006, 24(9):1395-1400.
200. Tondella M.L., Popovic T., Rosenstein N.E., et al. Distribution of Neisseria meningitidis serogroup B serosubtypes and serotypes circulating in the United States. The Active Bacterial Core Surveillance Team. J. Clin. Microbiol. 2000, 38(9):3323-3328.
201. Traore Y., Njanpop-Lafourcade B.M., Adjogble K.L., et al. The rise and fall of epidemic Neisseria meningitidis serogroup W135 meningitis in Burkina Faso, 2002-2005. Clin. Infect. Dis. 2006, 43(7):817-822.
202. Trotter C.L., Andrews N.J., Kaczmarski E.B., Miller E., Ramsay M.E. Effectiveness of meningococcal serogroup C conjugate vaccine 4 years after introduction. Lancet 2004, 364(9431):365-367.
203. Trotter C.L., Ramsay M.E. Vaccination against meningococcal disease in Europe: review and recommendations for the use of conjugate vaccines. FEMS Microbiol. Rev. 2007, 31(1):101-107.
204. Trotter C.L., Ramsay M.E., Gray S., Fox A., Kaczmarski E. No evidence for capsule replacement following mass immunisation with meningococcal serogroup C conjugate vaccines in England and Wales. Lancet Infect. Dis. 2006, 6(10):616-617. author reply 617-618.
205. Twumasi P.A., Kumah S., Leach A., et al. A trial of a group A plus group C meningococcal polysaccharide-protein conjugate vaccine in African infants. J. Infect. Dis. 1995, 171(3):632-638.
206. Tzeng Y.L., Stephens D.S. Epidemiology and pathogenesis of Neisseria meningitidis. Microbes Infect. 2000, 2(6):687-700.
207. van de Beek D., de Gans J., McIntyre P., Prasad K. Steroids in adults with acute bacterial meningitis: a systematic review. Lancet Infect. Dis. 2004, 4(3):139-143.
208. Vieusseux M. Memoire sur la maladie qui a regne a Geneva au printemps de 1805. J. Med. Chir. Pharm. 1805, 11:163-182.
209. Vincent J.L., Nadel S., Kutsogiannis D.J., et al. Drotrecogin alfa (activated) in patients with severe sepsis presenting with purpura fulminans, meningitis, or meningococcal disease: a retrospective analysis of patients enrolled in recent clinical studies. Crit. Care, 2005, 9(4):R331-R343.
210. Virji M., Makepeace K., Ferguson D.J., Achtman M., Moxon E.R. Meningococcal Opa and Opc proteins: their role in colonization and invasion of human epithelial and endothelial cells. Mol. Microbiol. 1993, 10(3):499-510.
211. Vogel U., Claus H., Frosch M. Rapid serogroup switching in Neisseria meningitidis. N. Engl. J. Med. 2000, 342(3):219-220.
212. Vu D.M., Kelly D., Heath P.T., McCarthy N.D., Pollard A.J., Granoff D.M. Effectiveness analyses may underestimate protection of infants after group C meningococcal immunization. J. Infect. Dis. 2006, 194(2):231-237.
213. Weichselbaum A. Ueber die Aetiologie der akuten meningitis cerebrospinalis. Fortschr. Med. 1887, 5:573.
214. Weis N., Lind I. Epidemiological markers in Neisseria meningitidis: an estimate of the performance of genotyping vs phenotyping. Scand. J. Infect. Dis. 1998, 30(1):69-75.
215. Weisfelt M., Hoogman M., van de Beek D., de Gans J., Dreschler W.A., Schmand B.A. Dexamethasone and long-term outcome in adults with bacterial meningitis. Ann. Neurol. 2006, 60(4):456-468.
216. Welte R., van den Dobbelsteen G., Bos J.M., et al. Economic evaluation of meningococcal serogroup C conjugate vaccination programmes in The Netherlands and its impact on decision-making. Vaccine 2004, 23(4):470-479.
217. West D., Reddin K., Matheson M., et al. Recombinant Neisseria meningitidis transferrin binding protein A protects against experimental meningococcal infection. Infect. Immun. 2001, 69(3):1561-1567.
218. White B., Livingstone W., Murphy C., Hodgson A., Rafferty M., Smith O.P. An open-label study of the role of adjuvant hemostatic support with protein C replacement therapy in purpura fulminans-associated meningococcemia. Blood 2000, 96(12):3719-3724.
219. Wiese-Posselt M., Hellenbrand W., Siedler A., Mayer C. Universal childhood immunisation with pneumococcal vaccine and meningococcal serogroup C vaccine introduced in Germany. Euro. Surveill. 2006, 11(9). E060907 4.
220. Wiesner P.J., Tronca E., Bonin P., Pedersen A.H., Holmes K.K. Clinical spectrum of pharyngeal gonococcal infection. N. Engl. J. Med. 1973, 288(4):181-185.
221. Wilder-Smith A., Goh K.T., Barkham T., Paton N.I. Hajj-associated outbreak strain of Neisseria meningitidis serogroup W135: estimates of the attack rate in a defined population and the risk of invasive disease developing in carriers. Clin. Infect. Dis. 2003, 36(6):679-683.
222. Winstead J.M., McKinsey D.S., Tasker S., De Groote M.A., Baddour L.M. Meningococcal pneumonia: characterization and review of cases seen over the past 25 years. Clin. Infect. Dis. 2000, 30(1):87-94.
223. Wong S., Lennon D., Jackson C., et al. New Zealand epidemic strain meningococcal B outer membrane vesicle vaccine in children aged 16-24 months. Pediatr. Infect. Dis. J. 2007, 26(4):345-350.
224. Wright J.C., Williams J.N., Christodoulides M., Heckels J.E. Immunization with the recombinant PorB outer membrane protein induces a bactericidal immune response against Neisseria meningitidis. Infect. Immun. 2002, 70(8):4028-4034.
225. Young L.S., LaForce F.M., Head J.J., Feeley J.C., Bennett J.V. A simultaneous outbreak of meningococcal and influenza infections. N. Engl. J. Med. 1972, 287(1):5-9.
226. Zangwill K.M., Stout R.W., Carlone G.M., et al. Duration of antibody response after meningococcal polysaccharide vaccination in US Air Force personnel. J. Infect. Dis. 1994, 169(4):847-852.
227. Zhu D., Barniak V., Zhang Y., Green B., Zlotnick G. Intranasal immunization of mice with recombinant lipidated P2086 protein reduces nasal colonization of group B Neisseria meningitidis. Vaccine 2006, 24(26):5420-5425.
228. Zhu D., Zhang Y., Barniak V., Bernfield L., Howell A., Zlotnick G. Evaluation of recombinant lipidated P2086 protein as a vaccine candidate for group B Neisseria meningitidis in a murine nasal challenge model. Infect. Immun. 2005, 73(10):6838-6845.
229. Zimmer S.M., Stephens D.S. Meningococcal conjugate vaccines. Expert Opin. Pharmacother. 2004, 5(4):855-863.
230. Zimmer S.M., Stephens D.S. Serogroup B meningococcal vaccines. Curr. Opin. Investig. Drugs, 2006, 7(8):733-739.